SoftServe Acquires Hoverstate
7.6.2023 16:01:00 EEST | Business Wire | Press release
SoftServe, a global IT consulting firm, today announced its acquisition of Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. The acquisition positions both companies as a single software solution source for digital native organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005221/en/
SoftServe, a global IT consulting firm, has announced acquiring Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. (Graphic: Business Wire)
SoftServe’s dynamic offerings and global footprint enhance Hoverstate’s intelligent process automation expertise and its key partnership with the Pega Platform from Pegasystems, the low-code platform provider empowering the world’s leading enterprises to Build for Change®. Clients now have deeper access to accelerated cloud-based digital processes and increased developmental efficiencies using data and analytics, AI/ML, and experience-based software engineering.
“As a SoftServe company, Hoverstate expands our suite of innovative services to help our clients streamline processes and minimize costs in today’s macroeconomic environment,” said Chris Baker, SoftServe CEO. “Hoverstate takes a human-centric approach that results in amazing user experiences and robust business outcomes that will be amplified across SoftServe’s clients and prospects.”
Hoverstate is already known for helping companies improve customer service, deepen engagement, and reduce operating costs by up to 50% across industries. The acquisition reinforces and extends SoftServe’s industry expertise in the healthcare, life science, banking, financial services, transportation, and logistics sectors. It also further amplifies Hoverstate’s status as a Specialized Pega Partner for the platform’s solutions to a global client marketplace.
Hoverstate’s expertise with the Pega Platform accelerates the cost optimization associated with back-office process transformation. Their reputational design-driven approach to the front-end ensures deeper customer engagement. Further, Hoverstate brings marquee healthcare organizations to SoftServe's client list. These organizations will accelerate business outcomes by leveraging their existing investments in technology solutions provided by Amazon Web Services, Google, Microsoft, NVIDIA, and SiteCore. Hoverstate’s holistic methodology enhanced by SoftServe’s AI/ML and advisory capabilities will create profound business outcomes for clients.
SoftServe has more than 12,000 associates spanning 14 countries in North America, EMEA, APAC, and Latin America. Along with Hoverstate’s footprint in offices across the U.S. and Italy, Hoverstate Chief Strategy Officer and Managing Partner Rob Fauver will accompany Chief Innovation Officer and Managing Partner Kyung Ahn as part of the SoftServe family.
“We believe joining a strong digital transformation services provider is the best path to deliver increased capabilities and exceptional digital solutions to our clients,” Fauver said. “SoftServe shares our people-first values. The cultural synergies between the firms are unmatched. SoftServe’s global delivery network gets us closer to our clients. It makes our support agile and scalable. We’re ready for the future.”
To learn more about SoftServe acquiring Hoverstate, please visit this webpage.
ABOUT SOFTSERVE
SoftServe is a leading IT consulting company transforming and optimizing how enterprises and software companies do business. Our end-to-end approach assures innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
ABOUT HOVERSTATE
Hoverstate is a full-service digital agency focusing on digital strategy, mobile apps, web development and business applications with a deep expertise in the health insurance, pharmaceutical, and life sciences industries. The main capabilities are: AppDev, Service Design/CX/UX, UI, DevOps & Infrastructure, Big Data, AI/ML, RPA, Consultancy across primarily Healthcare and Media, Education, Financial Services verticals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005221/en/
Contact information
Kayla Cash
Public Relations Manager
SoftServe, Inc.
kcash@softserveinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom